ORLANDO, Fla. and DUBLIN, Ireland, Jan. 14, 2015
/PRNewswire/ -- Immune Therapeutics Inc. (OTC:BB IMUN), a
specialty pharmaceutical company involved in the manufacture,
commercialization, distribution and marketing of novel, patented
therapies to combat chronic, life-threatening diseases through the
activation and modulation of the body's immune system, today
announced the appointment of Seth
Elliot as President and Chief Operating Officer.
As part of the changes in management, Dr. Eugene Youkilis and Christopher Pearce have stepped down as officers
of Immune Therapeutics but will continue to serve as members of the
board of directors. Christopher
Pearce will also continue to serve as a director of Airmed
Biopharma Limited and Sr. Vice President of TNI BioTech
International, Ltd.
Ms. Noreen Griffin, Chief
Executive Officer of Immune Therapeutics, stated, "We are very
excited to bring on Mr. Elliott to the Company's management team.
He brings tremendous operational, M & A, sales and marketing,
and financial leadership to the table. The company believes that we
can leverage his years of experience and expertise to move into
sales, marketing and commercialization of our specialty
pharmaceutical products. Mr. Elliott brings a proven track record,
knowledge and relationships in the field of marketing, strategy and
operational execution and will prove to be a strong asset to the
company."
Seth Elliott assumed the role as
President and Chief Operating Officer on January 13, 2015. Mr. Elliot has spent more than
15 years as a founder or senior executive of emerging growth and
middle market enterprises. He has helped to accelerate corporate
growth in diverse markets, on behalf of a variety of companies
through economic conditions ranging from boom to bust, developing a
rare combination of experience, vision, leadership and business
intuition.
Highlights of his professional background include:
As Chief Strategy Officer of Engagement Media Technologies, Mr.
Elliott was recruited by investors to pivot the business model,
optimize the product and reposition the company's efforts to focus
on marketing activation, research and intelligence. He proved a key
leader in the company's turnaround and was instrumental in securing
critical business development partnerships and managing several key
acquisitions.
As Vice President, Business Development for FastCall, he
collaborated on business model ideation and evaluate strategy in
regards to product-market fit for this venture backed marketing
automation enterprise. Mr. Elliott managed each step in the
business development deal process from strategy/planning, pipeline
development, prospecting, outreach, terms negotiation, contract
drafting and negotiation and implementation.
As the founder of Pegasus Advisory group, a consulting
organization, he provided business development and advisory
services to emerging growth companies. On behalf of RedBlizzard, a
proprietary Silverlight animation suite, he created a product
launch plan, including coordinating outreach to key Microsoft MVP's
for testing and review. He classified business development
segments, identified target opportunities, approached appropriate
individuals and formulated relevant business development offerings
in conjunction with the CEO of CityPockets, a NYC venture backed
startup in the Daily Deal space.
While advisor and Director of Copyright Control Services, Mr.
Elliott arranged a $25 million sale of the company to a NASDAQ
listed firm. He founded Sneakers.com, an internet sports retailer,
and secured a team that included the Founding CEO of The Sports
Authority, the former CEO of K-Mart stores and the Vice Chairman of
The North Face.
Mr. Elliott has previously served as an advisor to a number of
growth enterprises in industries such as healthcare, medical
devices, digital technology, media, ecommerce and entertainment and
actively participated in mergers & acquisitions transactions
and capital raises of more than $175
million in total value for these firms.
Mr. Elliott has spoken at conferences and workshops throughout
the globe and has been quoted as an industry expert in publications
such as Investors Business Daily, Smart Money,
Luxury Daily, Mobile Marketer, Fox News and
others.
"In a world that increasingly recognizes the importance of
immunotherapies in treating a host of life-threatening conditions,
Immune Therapeutics' assets and strategies have never been more
compelling," said Seth Elliott,
President and Chief Operating Officer. "I am incredibly
energized to help lead the company to its next phase of execution
tied with operational excellence, and I am particularly gratified
at the opportunity to be part of a leadership team that has the
potential to positively affect the lives of millions of people
throughout the world."
About Immune Therapeutics Inc.
We are a biotechnology company working to combat chronic,
life-threatening diseases through the activation and modulation of
the body's immune system using our patented immunotherapy. Our
products and immunotherapy technologies are designed to harness the
power of the immune system to improve the treatment of cancer,
infections such as HIV/AIDS, chronic inflammatory diseases, and
autoimmune diseases.
Our proprietary technology, therapies and patents include the
treatment of a wide range of cancers. Our most advanced clinical
programs involve immunotherapy with met-enkephalin (MENK)
(sometimes referred to as opioid growth factor) and our Low Dose
Naltrexone product (LDN) or Lodonal™, which have been shown to
stimulate the immune system even in patients with advanced
cancer.
Even though management considers any condition that results in
altered-immune response a target for investigation, we will most
likely pursue additional investigations for MENK and LDN as
valuable candidates in the treatment of autoimmune states such as
rheumatoid arthritis and multiple sclerosis; as an adjunct in
cancer patients undergoing chemotherapy, radiation treatments or
surgery; and as a complement to antibiotics in the treatment of a
variety of infectious diseases, including patients with HIV/AIDS,
in combination with retroviral drug therapy.
About Airmed Biopharma Limited
Airmed Biopharma Limited, our Irish subsidiary, is our
pharmaceutical sales division and is responsible for servicing
sales orders for Lodonal™ in countries where we have received sales
approval in Latin America and
Africa.
About TNI BioTech International, Ltd.
TNI BioTech International, Ltd., a BVI company and our
subsidiary, is responsible for managing our international
distribution.
About Cytocom, Inc.
Cytocom, Inc. is a biotechnology company that will initially
focus on developing LDN (Lodonal™) and MENK in the investigation of
unmet medical needs in the areas of oncological and inflammatory
diseases.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release and the statements of our management,
representatives and partners and our subsidiaries related thereto
include various "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, which
represent our expectations or beliefs concerning future events.
Statements containing expressions such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" used in
this press releases and in our filings with the Securities and
Exchange Commission as well as Disclosure Statements and Reports
filed with the Over The Counter Markets through the OTC Disclosure
and News Service are intended to identify forward-looking
statements. All forward-looking statements involve assumptions and
significant risks and uncertainties. Readers are cautioned that
certain important factors may affect our actual results and could
cause such results to differ materially from any forward-looking
statements that may be made in this news release, and thus readers
are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date thereof. Actual results
may differ significantly from those set forth in the
forward-looking statements. We undertake no obligation to publicly
release any revisions to such forward-looking statements to reflect
events or circumstances after the date hereof.
For further information, please see
http://www.tnibiotech.com.
Contact: Dennis S. Dobson
President and CEO
Dobson Media Group and
International Investor Relations Services Inc.
203-258-0159
www.dobsonmediagroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immune-therapeutics-inc-announces-appointment-of-new-president-and-chief-operating-officer-300020565.html
SOURCE Immune Therapeutics Inc.